Picture of IQ-AI logo

IQAI IQ-AI News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

REG - IQ-AI Limited - Imaging Biometrics Announces Channel Partnership

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220711:nRSK9294Ra&default-theme=true

RNS Number : 9294R  IQ-AI Limited  11 July 2022

IQ-AI Limited

("IQ-AI" or the "Company")

 

Imaging Biometrics Announces Channel Partnership

 

IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its
medical imaging analysis software, IB Clinic®, is now available via the newly
launched Bayer Calantic platform. This latest distribution partnership
continues IQ-AI's strategy of making IB Clinic's unique quantitative solutions
accessible through widespread, global networks and marks the culmination of
previously announced integration and validations efforts initiated in 2021.

Artificial intelligence (AI) marketplace platforms provide clinicians with a
one-stop-shop for a wide array of medical imaging solutions. These platforms
simplify and streamline access to proven tools, allowing clinicians to easily
harness the exclusive capabilities that can benefit patients. IQ-AI intends to
accelerate adoption of IB Clinic for healthcare providers through these global
networks.

"Whilst it is too soon to predict the revenue impact of this new partnership,
we are hopeful that it marks a significant expansion of availability
globally," said Trevor Brown, CEO of IQ-AI.

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering
quantitative imaging platforms and therapeutics that transform how clinicians
diagnose and treat patients more efficiently and effectively. For more
information about Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com (http://www.imagingbiometrics.com)

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

-ENDS-

 

For further information, please contact:

 IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

 

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering
quantitative imaging platforms and therapeutics that transform how clinicians
diagnose and treat patients more efficiently and effectively. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law
(as defined in the European Union (Withdrawal) Act 2018).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTURARRUNUBAUR

Recent news on IQ-AI

See all news